ME03421B - 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba - Google Patents
1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotrebaInfo
- Publication number
- ME03421B ME03421B MEP-2019-88A MEP201988A ME03421B ME 03421 B ME03421 B ME 03421B ME P201988 A MEP201988 A ME P201988A ME 03421 B ME03421 B ME 03421B
- Authority
- ME
- Montenegro
- Prior art keywords
- triazoles
- nuclear transport
- transport modulators
- modulators
- nuclear
- Prior art date
Links
- 150000000178 1,2,4-triazoles Chemical class 0.000 title 1
- 230000025308 nuclear transport Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361838172P | 2013-06-21 | 2013-06-21 | |
| PCT/US2014/043479 WO2014205389A1 (en) | 2013-06-21 | 2014-06-20 | Nuclear transport modulators and uses thereof |
| EP14738998.5A EP3010892B8 (en) | 2013-06-21 | 2014-06-20 | 1,2,4-triazoles as nuclear transport modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03421B true ME03421B (me) | 2020-01-20 |
Family
ID=51177201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-88A ME03421B (me) | 2013-06-21 | 2014-06-20 | 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US9738624B2 (me) |
| EP (2) | EP3492455B1 (me) |
| JP (2) | JP6730922B2 (me) |
| KR (2) | KR102322794B1 (me) |
| CN (3) | CN105339358B (me) |
| AU (5) | AU2014284168B2 (me) |
| BR (1) | BR112015032071B1 (me) |
| CA (1) | CA2915365C (me) |
| CY (1) | CY1122730T1 (me) |
| DK (2) | DK3492455T3 (me) |
| EA (1) | EA029743B1 (me) |
| ES (2) | ES2724275T3 (me) |
| HR (1) | HRP20190524T1 (me) |
| HU (1) | HUE042800T2 (me) |
| IL (2) | IL243099B (me) |
| LT (1) | LT3010892T (me) |
| ME (1) | ME03421B (me) |
| MX (1) | MX365939B (me) |
| PL (1) | PL3010892T3 (me) |
| PT (1) | PT3010892T (me) |
| RS (1) | RS58581B1 (me) |
| SG (1) | SG11201510036TA (me) |
| SI (1) | SI3010892T1 (me) |
| SM (1) | SMT201900184T1 (me) |
| TR (1) | TR201904455T4 (me) |
| UA (1) | UA119238C2 (me) |
| WO (1) | WO2014205389A1 (me) |
| ZA (1) | ZA201509015B (me) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103002742B (zh) | 2010-03-05 | 2016-07-13 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
| WO2012099807A1 (en) | 2011-01-17 | 2012-07-26 | Karyopharm Therapeutics, Inc. | Olefin containing nuclear transport modulators and uses thereof |
| PL3333164T3 (pl) | 2011-07-29 | 2023-12-18 | Karyopharm Therapeutics Inc. | Modulatory transportu jądrowego zawierające ugrupowanie hydrazydu i ich zastosowania |
| US9428490B2 (en) | 2011-07-29 | 2016-08-30 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| EA036639B1 (ru) | 2012-05-09 | 2020-12-02 | Байоджен Ма Инк. | Модуляторы ядерного транспорта и их применение |
| US10202366B2 (en) | 2013-03-15 | 2019-02-12 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using CRM1 inhibitors |
| SMT201900184T1 (it) | 2013-06-21 | 2019-05-10 | Karyopharm Therapeutics Inc | 1,2,4-triazoli come modulatori di trasporto nucleare e loro usi |
| CA2957266A1 (en) | 2014-08-15 | 2016-02-18 | Karyopharm Therapeutics Inc. | Polymorphs of selinexor |
| EP3397634A1 (en) * | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| MA43529A (fr) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics Inc | Modulateurs de transport nucléaire et leurs utilisations |
| EP3512515A1 (en) * | 2016-09-16 | 2019-07-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| CN111836798B (zh) | 2018-01-10 | 2022-04-15 | 凯瑞康宁生物工程（武汉）有限公司 | 氯胺酮的前药、其组合物和用途 |
| WO2019232724A1 (en) * | 2018-06-06 | 2019-12-12 | Xw Laboratories, Inc. | Compounds as nuclear transport modulators and uses thereof |
| WO2020051294A1 (en) * | 2018-09-07 | 2020-03-12 | Karyopharm Therapeutics Inc. | The combination of xpo1 inhibitors and second agents for the treatment of prostate cancer |
| WO2020092965A1 (en) * | 2018-11-01 | 2020-05-07 | Karyopharm Therapeutics Inc. | E2f1 as a biomarker for treatments using xpo1 inhibitors |
| JP2022510736A (ja) | 2018-12-05 | 2022-01-27 | 株式会社スコヒアファーマ | 大環状化合物とその使用 |
| CN111606890A (zh) * | 2019-02-26 | 2020-09-01 | 微境生物医药科技(上海)有限公司 | 含丙烯酰基的核转运调节剂及其用途 |
| AU2020266170A1 (en) | 2019-05-01 | 2021-11-25 | Karyopharm Therapeutics Inc. | Process for preparing XPO1 inhibitors and intermediates for use in the preparation of XP01 inhibitors |
| WO2021202745A1 (en) | 2020-03-31 | 2021-10-07 | Karyopharm Therapeutics Inc. | Treatment of covid-19 with a sine compound |
| CN113880803B (zh) * | 2020-07-03 | 2024-07-02 | 上海天慈国际药业有限公司 | 一种xpo-1抑制剂的制备方法 |
| WO2022089629A1 (zh) * | 2020-11-02 | 2022-05-05 | 江苏柯菲平医药股份有限公司 | 1,2,4-三氮唑衍生物及其制备方法和用途 |
| CN112294819B (zh) * | 2020-12-03 | 2021-12-14 | 中国人民解放军军事科学院军事医学研究院 | 一种炎症小体抑制剂及其应用 |
| CN113045550A (zh) * | 2021-03-12 | 2021-06-29 | 深圳济康医药科技有限公司 | 一种三氮唑类衍生物及其制备方法和应用 |
| CA3219525A1 (en) | 2021-05-20 | 2022-11-24 | Erkan Baloglu | Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms |
| CN113248474A (zh) * | 2021-05-24 | 2021-08-13 | 王能能 | 五元氮唑杂环衍生物及其制备方法和用途 |
| TWI844074B (zh) | 2021-08-13 | 2024-06-01 | 凱瑞康寧生技股份有限公司 | 氯胺酮衍生物之醫藥組成物及口服劑型 |
| CN117940409A (zh) * | 2021-09-08 | 2024-04-26 | 南京明德新药研发有限公司 | 丙烯酰胺类化合物及其应用 |
| JP2024539922A (ja) * | 2021-10-29 | 2024-10-31 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | ピリジル含有化合物 |
| WO2023134629A1 (zh) * | 2022-01-12 | 2023-07-20 | 上海海雁医药科技有限公司 | 核转运调节剂及其用途 |
| WO2024102477A1 (en) | 2022-11-11 | 2024-05-16 | Karyopharm Therapeutics Inc. | Crystalline forms of eltanexor and process for preparing same |
| TWI863768B (zh) * | 2023-12-21 | 2024-11-21 | 友達光電股份有限公司 | 顯示裝置 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS229934B2 (en) | 1981-07-07 | 1984-07-16 | Pfizer | Production method subst.indolylacryte acid derivative |
| KR840000529A (ko) | 1981-07-07 | 1984-02-25 | 콘스탄틴 루이스 클레멘트 | 인돌 유도체의 제조방법 |
| US4778796A (en) | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
| IL97249A (en) | 1990-02-23 | 1995-01-24 | Takeda Chemical Industries Ltd | Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or |
| JP3111321B2 (ja) | 1990-02-23 | 2000-11-20 | 武田薬品工業株式会社 | 縮合チアゾール化合物 |
| US5541213A (en) | 1993-06-24 | 1996-07-30 | Eisai Co., Ltd. | Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility |
| US5468353A (en) | 1994-05-05 | 1995-11-21 | Minnesota Mining And Manufacturing Company | Mist suppressant for solvent extraction metal electrowinning |
| AU4368996A (en) | 1994-11-23 | 1996-06-17 | Neurogen Corporation | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands |
| US20030018025A1 (en) | 1995-06-07 | 2003-01-23 | Neurogen Corporation, Corporation Of The State Of Delaware | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands |
| EP0858457A1 (de) | 1995-10-20 | 1998-08-19 | Dr. Karl Thomae GmbH | 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung |
| DE69736775T2 (de) | 1996-04-04 | 2007-08-23 | Shionogi & Co., Ltd. | Cephemverbindungen und medikamente die diese verbindungen enthalten |
| EP1360901A1 (en) | 1996-04-25 | 2003-11-12 | Nissan Chemical Industries, Limited | 2,3-cyclic substituted derivatives of 3-hydroxyacrolein and 3-hydroxyacrylic acid as pesticides |
| JP4054992B2 (ja) | 1996-04-25 | 2008-03-05 | 日産化学工業株式会社 | エチレン誘導体および有害生物防除剤 |
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| US5994398A (en) | 1996-12-11 | 1999-11-30 | Elan Pharmaceuticals, Inc. | Arylsulfonamides as phospholipase A2 inhibitors |
| JP4416198B2 (ja) | 1997-12-19 | 2010-02-17 | 武田薬品工業株式会社 | アニリド誘導体、その製造法および用途 |
| AU2960599A (en) | 1998-03-30 | 1999-10-18 | Akira Karasawa | Quinazoline derivatives |
| CO5271680A1 (es) | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
| EP2083005A1 (en) | 2000-09-29 | 2009-07-29 | TopoTarget UK Limited | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors |
| MXPA04002397A (es) | 2001-09-14 | 2004-12-02 | Methylgene Inc | Inhibidores de histona deacetilasa. |
| AU2003287965A1 (en) | 2002-10-24 | 2004-05-13 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
| DE10250743A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| JP4145230B2 (ja) | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
| BR0315815A (pt) | 2002-11-01 | 2005-09-13 | Takeda Pharmaceutical | Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto |
| AU2003291403A1 (en) | 2002-11-08 | 2004-06-03 | Neurogen Corporation | 3-substituted-6-aryl pyridined as ligands of c5a receptors |
| CA2512886A1 (en) | 2003-02-28 | 2004-09-10 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
| KR100966749B1 (ko) | 2004-05-26 | 2010-06-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 화합물 |
| BRPI0515015A (pt) | 2004-08-11 | 2008-07-01 | Kyorin Seiyaku Kk | derivado cìclico de ácido aminobenzóico; medicamento; agonista ppar(alpha); agonista duplo ppar(alpha), y; agonista duplo ppar(alpha), (delta); modulador ppar; agente lipìdeo; agente profilático ou terapêutico compreendendo pelo menos um dos derivados cìclicos de ácido aminobenzóico ou sal do mesmo farmacêuticamente aceitável |
| WO2006019020A1 (ja) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
| EP1849465A4 (en) | 2005-02-18 | 2008-12-24 | Takeda Pharmaceutical | AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR |
| RU2418793C2 (ru) | 2005-11-15 | 2011-05-20 | Оцука Фармасьютикал Ко., Лтд. | Соединение оксазола и фармацевтическая композиция |
| JP2007210929A (ja) | 2006-02-09 | 2007-08-23 | Sankyo Co Ltd | ウレア化合物を含有する医薬 |
| EA016464B1 (ru) | 2006-03-09 | 2012-05-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Полициклические производные арилимидазола |
| CN101466670B (zh) | 2006-04-07 | 2013-04-17 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| RU2435764C2 (ru) | 2006-04-18 | 2011-12-10 | Ниппон Кемифар Ко., Лтд. | АГЕНТ, АКТИВИРУЮЩИЙ РЕЦЕПТОР, АКТИВИРУЕМЫЙ ПРОЛИФЕРАТОРАМИ ПЕРОКСИСОМ δ |
| JP4999923B2 (ja) | 2006-06-13 | 2012-08-15 | 中国科学院上海薬物研究所 | 複素環非ヌクレオシド系化合物、抗ウィルス医薬組成物、及びウィルス性疾病治療薬物 |
| CA2658925C (en) | 2006-07-27 | 2015-07-14 | Amorepacific Corporation | Novel sulfonylamino acrylamide derivatives, isomer thereof,or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| TWI386405B (zh) | 2006-09-05 | 2013-02-21 | 咪唑衍生物 | |
| EP1942104A1 (en) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals |
| EP1939180A1 (en) | 2006-12-20 | 2008-07-02 | sanofi-aventis | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase |
| WO2008106047A2 (en) | 2007-02-26 | 2008-09-04 | Kosan Biosciences Incorporated | Carbamate compounds |
| EP2003118A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Zimtsäurederivate als Modulatoren des EP2-Rezeptors |
| EP2323737A2 (en) | 2008-08-08 | 2011-05-25 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| JP2012532889A (ja) | 2009-07-09 | 2012-12-20 | クレッシェンド セラピューティクス、エルエルシー | 創傷治療方法及び傷跡変性方法 |
| US8518968B2 (en) | 2009-12-04 | 2013-08-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hydrazone and diacyl hydrazine compounds and methods of use |
| CN103002742B (zh) | 2010-03-05 | 2016-07-13 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
| WO2012099807A1 (en) * | 2011-01-17 | 2012-07-26 | Karyopharm Therapeutics, Inc. | Olefin containing nuclear transport modulators and uses thereof |
| PL3333164T3 (pl) | 2011-07-29 | 2023-12-18 | Karyopharm Therapeutics Inc. | Modulatory transportu jądrowego zawierające ugrupowanie hydrazydu i ich zastosowania |
| US9428490B2 (en) | 2011-07-29 | 2016-08-30 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2013020024A2 (en) | 2011-08-03 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Maleimide compounds and methods of treatment |
| EA036639B1 (ru) | 2012-05-09 | 2020-12-02 | Байоджен Ма Инк. | Модуляторы ядерного транспорта и их применение |
| WO2014152263A1 (en) | 2013-03-15 | 2014-09-25 | Karyopharm Therapeutics Inc. | Exo olefin-containing nuclear transport modulators and uses thereof |
| US10202366B2 (en) | 2013-03-15 | 2019-02-12 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using CRM1 inhibitors |
| WO2014205393A1 (en) | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| SMT201900184T1 (it) | 2013-06-21 | 2019-05-10 | Karyopharm Therapeutics Inc | 1,2,4-triazoli come modulatori di trasporto nucleare e loro usi |
| US11567063B2 (en) | 2013-11-15 | 2023-01-31 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Methods for assessing cell viability or predicting cell response to a treatment using cell movement |
| WO2016015597A1 (en) | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
| CA2957266A1 (en) | 2014-08-15 | 2016-02-18 | Karyopharm Therapeutics Inc. | Polymorphs of selinexor |
| EP3397634A1 (en) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| MA43529A (fr) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics Inc | Modulateurs de transport nucléaire et leurs utilisations |
| US11034675B2 (en) | 2016-01-08 | 2021-06-15 | Dr. Reddy's Laboratories Limited | Solid forms of Selinexor and process for their preparation |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| US10993943B2 (en) | 2017-01-05 | 2021-05-04 | Watson Laboratories Inc. | Crystalline forms of selinexor and process for their preparation |
| EP3808742A1 (en) | 2019-10-16 | 2021-04-21 | Sandoz AG | Polymorph of selinexor |
| ES3001533T3 (en) | 2019-12-06 | 2025-03-05 | Bae Systems Plc | Light source |
| US20230391754A1 (en) | 2020-10-21 | 2023-12-07 | Karyopharm Therapeutics Inc. | Crystalline form of selinexor |
-
2014
- 2014-06-20 SM SM20190184T patent/SMT201900184T1/it unknown
- 2014-06-20 SI SI201431142T patent/SI3010892T1/sl unknown
- 2014-06-20 PT PT14738998T patent/PT3010892T/pt unknown
- 2014-06-20 RS RS20190400A patent/RS58581B1/sr unknown
- 2014-06-20 EP EP18202641.9A patent/EP3492455B1/en active Active
- 2014-06-20 PL PL14738998T patent/PL3010892T3/pl unknown
- 2014-06-20 HU HUE14738998A patent/HUE042800T2/hu unknown
- 2014-06-20 DK DK18202641.9T patent/DK3492455T3/da active
- 2014-06-20 WO PCT/US2014/043479 patent/WO2014205389A1/en not_active Ceased
- 2014-06-20 EA EA201690044A patent/EA029743B1/ru unknown
- 2014-06-20 CN CN201480035555.8A patent/CN105339358B/zh active Active
- 2014-06-20 LT LTEP14738998.5T patent/LT3010892T/lt unknown
- 2014-06-20 KR KR1020167001020A patent/KR102322794B1/ko active Active
- 2014-06-20 CA CA2915365A patent/CA2915365C/en active Active
- 2014-06-20 US US14/900,469 patent/US9738624B2/en active Active
- 2014-06-20 KR KR1020217035649A patent/KR102545732B1/ko active Active
- 2014-06-20 HR HRP20190524TT patent/HRP20190524T1/hr unknown
- 2014-06-20 TR TR2019/04455T patent/TR201904455T4/tr unknown
- 2014-06-20 JP JP2016521862A patent/JP6730922B2/ja active Active
- 2014-06-20 EP EP14738998.5A patent/EP3010892B8/en active Active
- 2014-06-20 CN CN201910389947.9A patent/CN110386919B/zh active Active
- 2014-06-20 ME MEP-2019-88A patent/ME03421B/me unknown
- 2014-06-20 ES ES14738998T patent/ES2724275T3/es active Active
- 2014-06-20 BR BR112015032071-6A patent/BR112015032071B1/pt active IP Right Grant
- 2014-06-20 DK DK14738998.5T patent/DK3010892T3/en active
- 2014-06-20 ES ES18202641T patent/ES2952774T3/es active Active
- 2014-06-20 SG SG11201510036TA patent/SG11201510036TA/en unknown
- 2014-06-20 UA UAA201600474A patent/UA119238C2/uk unknown
- 2014-06-20 AU AU2014284168A patent/AU2014284168B2/en active Active
- 2014-06-20 CN CN201910393112.0A patent/CN110183422B/zh active Active
- 2014-06-20 MX MX2015016983A patent/MX365939B/es active IP Right Grant
-
2015
- 2015-12-10 ZA ZA2015/09015A patent/ZA201509015B/en unknown
- 2015-12-14 IL IL243099A patent/IL243099B/en active IP Right Grant
-
2017
- 2017-07-17 US US15/651,856 patent/US10407405B2/en active Active
-
2018
- 2018-09-05 IL IL261612A patent/IL261612A/en unknown
-
2019
- 2019-01-10 AU AU2019200147A patent/AU2019200147A1/en not_active Abandoned
- 2019-03-26 CY CY20191100349T patent/CY1122730T1/el unknown
- 2019-07-23 US US16/519,955 patent/US11124493B2/en active Active
-
2020
- 2020-07-03 JP JP2020115772A patent/JP7061161B2/ja active Active
- 2020-11-23 AU AU2020277088A patent/AU2020277088B2/en active Active
-
2021
- 2021-08-23 US US17/409,150 patent/US11945794B2/en active Active
-
2022
- 2022-12-06 AU AU2022283662A patent/AU2022283662A1/en not_active Abandoned
-
2024
- 2024-02-23 US US18/586,019 patent/US20250059158A1/en active Pending
- 2024-07-12 AU AU2024204818A patent/AU2024204818A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03421B (me) | 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba | |
| CY2021028I1 (el) | Ρυθμιστες πυρηνικης μεταφορας περιεχοντες υδραζιδιο και χρησεις αυτων | |
| IL240196A0 (en) | Amide compounds, compositions comprising same and uses thereof | |
| AP2015008789A0 (en) | Heterocyclic compounds and their uses | |
| EP2894690A4 (en) | BAG FOR SECONDARY BATTERY AND SECONDARY BATTERY THEREWITH | |
| IL241374A0 (en) | History of benzimidazole and their use | |
| IL244383A0 (en) | Triazolone compounds and their uses | |
| EP2952513A4 (en) | AZOLBENZOLDERIVAT | |
| EP2837627A4 (en) | AMIDOPYRIDINE DERIVATIVE AND USE THEREOF | |
| EP3003504A4 (en) | Improvements in rope access equipment | |
| IL241772B (en) | Pyrazole derivatives, compositions comprising same and uses thereof | |
| EP3062822C0 (en) | CELL TRANSPORT | |
| FR3014422B1 (fr) | Ecarteur d'elingues | |
| GB201300474D0 (en) | Easy access rucksack | |
| GB2513481B (en) | An improved access platform | |
| SMP201400166B1 (it) | Chiusura, contenitore e loro uso | |
| BR302013000887S1 (pt) | "configuração aplicada em banco" | |
| TH1501007725B (th) | ลามิเนตและวัสดุบรรจุภัณฑ์โดยใช้สิ่งเดียวกันนั้น | |
| UA29179S (uk) | Контейнер для бальзаму | |
| UA27219S (uk) | Форматор-вулканізатор 75" та 88" | |
| GB201305454D0 (en) | An improved access platform | |
| GB201315589D0 (en) | Lock & load | |
| GB201313417D0 (en) | Portfolio management system | |
| UA29180S (uk) | Пакування для бальзаму | |
| BR302013001367S1 (pt) | "configuração aplicada em garrafa" |